HARMONY BIOSCIENCES HOLDINGS

HRMY is the ticker symbol for Harmony Biosciences Holdings, Inc., a biopharmaceutical company focused on developing and commercializing therapies for patients with rare neurological disorders. The stock trades on the Nasdaq Global Select Market under the symbol HRMY. Harmony's lead product, WAKIX (pitolisant), is approved in the U.S. for excessive daytime sleepiness in narcolepsy. As a commercial-stage biopharma, HRMY's value is closely tied to its product pipeline, regulatory milestones, and revenue growth.

The 52-week range shows the lowest and highest prices at which HRMY shares have traded over the past year. This range helps investors gauge recent price volatility. For the current 52-week high and low, please refer to the latest HRMY quote data displayed on this page, as these figures change with market activity.

Evaluating HRMY's valuation typically involves comparing its price to earnings, sales, or book value, and benchmarking these multiples against peers in the biopharmaceutical sector. Because HRMY is a commercial-stage company with a focused product portfolio, investors may also consider pipeline prospects, revenue growth, and profitability trends. Since valuation metrics are dynamic, please use the latest HRMY data shown on this page for current figures.

HRMY shares can be traded in pre-market and after-hours sessions through many brokerage platforms, though liquidity is often lower and spreads wider than during regular Nasdaq trading hours. Extended-hours trading carries additional risks, such as price volatility and limited order types. For the exact extended session times and availability, check with your broker and the current HRMY quote on this page.

Key metrics for HRMY include revenue growth, gross margin, operating expenses, net income, and cash flow, as these reflect the commercial performance of its products. For a biopharmaceutical company, investors also watch research and development spending and pipeline progress. Since these figures are reported periodically, please refer to the latest HRMY financial statements and disclosures for current data.

Investing in HRMY carries risks common to commercial-stage biopharmaceutical companies, including competition, regulatory hurdles, reliance on a limited number of products, and the potential for clinical or commercial setbacks. Broader market, economic, and interest rate changes can also affect the share price. For a comprehensive view, review HRMY's risk factors in its annual report and other SEC filings.